undamentalytics Newsletter
Sign in

Opus Genetics, Inc. cash flow statement

In fiscal 2025, Opus Genetics, Inc.'s operations generated −$35.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$35.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−5−7−16−7−8−4−7−1914−1−26−35−41
Depreciation and amortisation0000000000000
Stock-based pay0110102224334
Capital spending—————0000000—
Free cash flow—————−4−7−1914−1−26−35—
Free cash flow after stock pay—————−4−8−2113−5−29−39—
Share buybacks000——————————
Shares issued11913710802849468

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: CRBU vs IRDIRD vs RLAYHYFT vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Opus Genetics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Opus Genetics, Inc.